53 Healthcare stocks with rising earnings estimates (Nov 2026)
53 Healthcare stocks with rising earnings estimates by the Lician Quant rating as of Nov 4, 2026, including Halozyme Therapeutics Inc (HALO), Bio-Techne Corp (TECH), Iovance Biotherapeutics Inc (IOVA). EPS Revisions grade A- or better (analysts raising current and next-quarter EPS estimates over 30 and 90 days) and a Buy or Strong Buy rating.
Open this screen in the full screener to add filters, sort by any factor and save it.
53 stocks · Strong Buy or Buy · Healthcare · EPS Revisions ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1OMEROmeros Corporation | 4.86Strong Buy | C | — | — | A- | A+ | $1.2B | 9.6 | — | — | 20.4% | Nov 12 |
| 2OPKOpko Health Inc | 4.61Strong Buy | B+ | F | A | A | A+ | $1.3B | 10.8 | -3.8% | — | 9.1% | Nov 4 |
| 3RLMDRelmada Therapeutics Inc | 3.97Buy | C+ | — | C- | C | A+ | $349M | NM | — | — | — | Nov 12 |
| 4EDITEditas Medicine Inc | 3.52Buy | C | A- | D- | D+ | A+ | $261M | NM | +20.8% | — | — | Nov 9 |
| 5IOVAIovance Biotherapeutics Inc | 3.64Buy | F | — | D | A | A+ | $6.4B | NM | +34.5% | — | 15.2% | Nov 5 |
| 6GRALGRAIL, LLC | 4.48Buy | D+ | A- | D+ | A | A+ | $5.6B | NM | +23.1% | — | 24.4% | Nov 4 |
| 7LUNGPulmonx Corp | 4.27Buy | B | C- | D+ | A+ | A+ | $129M | NM | -3.4% | — | 1.8% | — |
| 8RNAAtrium Therapeutics, Inc. Common Stock | 3.61Buy | B- | A+ | F | D | A+ | $141M | NM | +235.3% | — | — | Nov 12 |
| 9CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 10AVXLAnavex Life Sciences Corp | 3.59Buy | B+ | — | C+ | F | A+ | $121M | NM | — | — | — | Nov 24 |
| 11CSTLCastle Biosciences Inc | 4.33Buy | C- | B- | B- | B+ | A+ | $986M | NM | +3.2% | — | 7.6% | Nov 5 |
| 12SENSSenseonics Holdings, Inc. Common Stock | 4.06Buy | D+ | A | F | A- | A+ | $391M | NM | +90.6% | — | — | Nov 9 |
| 13ASTHAstrana Health Inc | 4.93Strong Buy | A+ | A | B | C | A+ | $1.8B | 44.0 | +58.9% | — | 8.0% | Nov 5 |
| 14TEMTempus AI, Inc. Class A Common Stock | 4.31Buy | — | B | D+ | B | A+ | — | — | +50.4% | — | — | — |
| 15HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 16SEPNSepterna, Inc. Common Stock | 4.17Buy | D- | B | C+ | A+ | A+ | $1.9B | NM | +13,520% | — | — | Nov 9 |
| 17AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 18SGHTSight Sciences Inc | 3.84Buy | D | D+ | C | A+ | A | $494M | NM | +9.3% | — | — | Nov 4 |
| 19STIMNeuronetics Inc | 3.88Buy | C- | A | D+ | C | A | $166M | NM | +39.6% | — | — | Nov 4 |
| 20ADPTAdaptive Biotechnologies Corp | 4.00Buy | F | A- | C+ | B+ | A | $4.4B | NM | +50.1% | — | — | Nov 4 |
| 21TECHBio-Techne Corp | 4.50Strong Buy | B | C | A- | B- | A | $11.3B | 62.4 | -0.4% | — | 4.9% | Nov 4 |
| 22FTREFortrea Holdings Inc. | 4.16Buy | B | F | B- | A | A | $2.2B | NM | -2.1% | — | 9.0% | — |
| 23CARLCarlsmed, Inc. Common Stock | 3.54Buy | D- | — | C- | B | A | $429M | NM | — | — | — | Nov 10 |
| 24ANIKAnika Therapeutics Inc | 4.25Buy | B | C- | B- | B | A | $285M | NM | +31.4% | — | 3.6% | Nov 6 |
| 25URGNUroGen Pharma Ltd | 3.77Buy | F | A | C | C+ | A | $1.7B | NM | +100.3% | — | — | Nov 4 |
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Rising EPS estimates in other sectors
About this screen
- Which are the top Healthcare stocks with rising earnings estimates?
- As of Nov 4, 2026, the highest ranked are Omeros Corporation (OMER, rating 4.86); Opko Health Inc (OPK, rating 4.61); Relmada Therapeutics Inc (RLMD, rating 3.97); Editas Medicine Inc (EDIT, rating 3.52); Iovance Biotherapeutics Inc (IOVA, rating 3.64). 53 stocks pass the screen in total.
- What does this screen look for?
- EPS Revisions grade A- or better (analysts raising current and next-quarter EPS estimates over 30 and 90 days) and a Buy or Strong Buy rating.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.